Malcolm Brenner, MD, PhD

Full Affiliate Member, Research Institute
Houston Methodist


Dr. Brenner completed his postdoctoral training in 1981 and joined the Clinical Research Centre of Northwick Park Hospital in London, England as a MRC Clinical Scientist and Honorary Senior Registrar. He also began lecturing in Haematology at the Royal Free Hospital and Hospital for Sick Children, also in London.

Dr. Brenner joined the faculty at the University of Tennessee in Memphis as a Professor in the Departments of Pediatrics and Medicine in 1990. He also became the Director of the Bone Marrow Transplant Division of the St. Jude Children's Research Hospital that same year. He later directed the Cell and Gene Therapy Program at St. Jude's from 1994 until 1997, when he assumed his current positions at the Baylor College of Medicine.

Description of Research

Dr. Brenner's research focuses on gene transfer to stem cells and to effector cells of the immune system. His research group was one of the first to use gene transfer in human subjects, establishing the feasibility of tracking human stem cells and their progeny in subjects with cancer. Dr. Brenner also develops tumor vaccines for pediatric and hematological malignancies, using genetic modification with retroviral and adenoviral vectors.

Areas Of Expertise

Stem cells Gene therapy Cell therapy Vectors
Education & Training

PhD, University of Cambridge

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
Musher, BL, Rowinsky, EK, Smaglo, BG, Abidi, W, Othman, M, Patel, K, Jawaid, S, Jing, J, Brisco, A, Leen, AM, Wu, M, Sandin, LC, Wenthe, J, Eriksson, E, Ullenhag, GJ, Grilley, B, Leja-Jarblad, J, Hilsenbeck, SG, Brenner, MK & Loskog, ASI 2024, , The Lancet Oncology, vol. 25, no. 4, pp. 488-500.

Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
Hegde, M, Navai, S, DeRenzo, C, Joseph, SK, Sanber, K, Wu, M, Gad, AZ, Janeway, KA, Campbell, M, Mullikin, D, Nawas, Z, Robertson, C, Mathew, PR, Zhang, H, Mehta, B, Bhat, RR, Major, A, Shree, A, Gerken, C, Kalra, M, Chakraborty, R, Thakkar, SG, Dakhova, O, Salsman, VS, Grilley, B, Lapteva, N, Gee, A, Dotti, G, Bao, R, Salem, AH, Wang, T, Brenner, MK, Heslop, HE, Wels, WS, Hicks, MJ, Gottschalk, S & Ahmed, N 2024, , Nature Cancer.

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
Hill, LQC, Rouce, RH, Wu, MJ, Wang, T, Ma, R, Zhang, H, Mehta, B, Lapteva, N, Mei, Z, Smith, TS, Yang, L, Srinivasan, M, Burkhardt, PM, Ramos, CA, Lulla, P, Arredondo, M, Grilley, B, Heslop, HE, Brenner, MK & Mamonkin, M 2024, , Blood, vol. 143, no. 13, pp. 1231-1241.

Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis
Mo, F, Tsai, CT, Zheng, R, Cheng, C, Heslop, HE, Brenner, MK, Mamonkin, M & Watanabe, N 2024, , Cytotherapy.

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients
Vasileiou, S, Hill, LQ, Kuvalekar, M, Workineh, AG, Watanabe, A, Velazquez, Y, Lulla, S, Mooney, K, Lapteva, N, Grilley, BJ, Heslop, HE, Rooney, CM, Brenner, MK, Eagar, TN, Carrum, G, Grimes, KA, Leen, AM & Lulla, P 2023, , Haematologica, vol. 108, no. 7, pp. 1840-1850.

Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival
Martinez, C, Aguayo-Hiraldo, P, Chaimowitz, N, Forbes, L, Rider, N, Nicholas, S, Seeborg, F, Chinen, J, Chinn, I, Davis, C, Roseblatt, H, Noroski, L, Omer, B, John, T, Yassine, K, Naik, S, Craddock, J, Bhar, S, Allen, C, Ahmed, N, Sasa, G, Steffin, D, Doherty, E, George, A, Salem, B, Friend, B, Hegde, M, Brenner, MK, Heslop, HE, Leen, A, Peña, A, Wu, M, Hanson, IC & Krance, RA 2023, , Blood Advances, vol. 7, no. 9, pp. 1823-1830.

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: Implications for T-cell immunotherapy
Sharma, S, Woods, M, Mehta, NU, Sauer, T, Parikh, KS, Schmuck-Henneresse, M, Zhang, H, Mehta, B, Brenner, MK, Heslop, HE & Rooney, CM 2023, , Journal for immunotherapy of cancer, vol. 11, no. 4, jitc-2022-006267.

Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies
Wang, D, Porter, CE, Lim, B, Shaw, AR, Robertson, CS, Woods, ML, Xu, Y, Biegert, GGW, Morita, D, Wang, T, Grilley, BJ, Heslop, H, Brenner, MK & Suzuki, M 2023, , Science advances, vol. 9, no. 13, eade6790, pp. eade6790.

Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials
Cornetta, K, Yao, J, House, K, Duffy, L, Adusumilli, PS, Beyer, R, Booth, C, Brenner, M, Curran, K, Grilley, B, Heslop, H, Hinrichs, CS, Kaplan, RN, Kiem, HP, Kochenderfer, JN, Kohn, DB, Mailankody, S, Norberg, SM, OCearbhaill, RE, Pappas, J, Park, J, Ramos, C, Ribas, A, Rivière, I, Rosenberg, SA, Sauter, C, Shah, NN, Slovin, SF, Thrasher, A, Williams, DA & Lin, TY 2023, , Molecular Therapy, vol. 31, no. 3, pp. 801-809.

Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma
McKenna, MK, Ozcan, A, Brenner, D, Watanabe, N, Legendre, M, Thomas, DG, Ashwood, C, Cummings, RD, Bonifant, C, Markovitz, DM & Brenner, MK 2023, , Journal for immunotherapy of cancer, vol. 11, no. 1, A10.

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation
Mo, F, Watanabe, N, Omdahl, KI, Burkhardt, PM, Ding, X, Hayase, E, Panoskaltsis-Mortari, A, Jenq, RR, Heslop, HE, Kean, LS, Brenner, M, Tkachev, V & Mamonkin, M 2023, , Blood, vol. 141, no. 10, pp. 1194-1208.

Emerging Challenges to Cellular Therapy of Cancer
Lulla, PD & Brenner, M 2023, , Cancer Journal (United States), vol. 29, no. 1, pp. 20-27.

Targeting glycans for CAR therapy: The advent of sweet CARs
Raglow, Z, McKenna, MK, Bonifant, CL, Wang, W, Pasca di Magliano, M, Stadlmann, J, Penninger, JM, Cummings, RD, Brenner, MK & Markovitz, DM 2022, , Molecular Therapy, vol. 30, no. 9, pp. 2881-2890.

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs
Steffin, DHM, Muhsen, IN, Hill, LQC, Ramos, CA, Ahmed, N, Hegde, M, Wang, T, Wu, M, Gottschalk, S, Whittle, SB, Lulla, PD, Mamonkin, M, Omer, B, Rouce, RH, Heczey, A, Metelitsa, LS, Grilley, BJ, Robertson, C, Torrano, V, Lapteva, N, Gee, AP, Rooney, CM, Brenner, MK & Heslop, HE 2022, , Blood, vol. 140, no. 1, pp. 16-24.

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL
Naik, S, Vasileiou, S, Tzannou, I, Kuvalekar, M, Watanabe, A, Robertson, C, Lapteva, N, Tao, W, Wu, M, Grilley, B, Carrum, G, Kamble, RT, Hill, LQ, Krance, RA, Martinez, C, Tewari, P, Omer, B, Gottschalk, S, Heslop, HE, Brenner, MK, Rooney, CM, Vera, JF, Leen, AM & Lulla, PD 2022, , Blood, vol. 139, no. 17, pp. 2706-2711.

Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy
Atilla, PA, McKenna, MK, Watanabe, N, Mamonkin, M, Brenner, MK & Atilla, E 2022, , Cytotherapy, vol. 24, no. 3, pp. 282-290.

Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies
Watanabe, N, Mo, F, Zheng, R, Ma, R, Bray, VC, van Leeuwen, DG, Sritabal-Ramirez, J, Hu, H, Wang, S, Mehta, B, Srinivasan, M, Scherer, LD, Zhang, H, Thakkar, SG, Hill, LQC, Heslop, HE, Cheng, C, Brenner, MK & Mamonkin, M 2023, , Molecular Therapy, vol. 31, no. 1, pp. 24-34.

Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors
Rosewell Shaw, A, Porter, CE, Yip, T, Mah, WC, McKenna, MK, Dysthe, M, Jung, Y, Parihar, R, Brenner, MK & Suzuki, M 2021, , Communications Biology, vol. 4, no. 1, 368.

Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity: Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity (Molecular Therapy (2021) 29(5) (1808–1820), (S152500162100071X), (10.1016/j.ymthe.2021.02.004))
McKenna, MK, Englisch, A, Brenner, B, Smith, T, Hoyos, V, Suzuki, M & Brenner, MK 2021, , Molecular Therapy, vol. 29, no. 12, pp. 3529-3533.

Evidence generation and reproducibility in cell and gene therapy research: A call to action
Abou-el-Enein, M, Angelis, A, Appelbaum, FR, Andrews, NC, Bates, SE, Bierman, AS, Brenner, MK, Cavazzana, M, Caligiuri, MA, Clevers, H, Cooke, E, Daley, GQ, Dzau, VJ, Ellis, LM, Fineberg, HV, Goldstein, LSB, Gottschalk, S, Hamburg, MA, Ingber, DE, Kohn, DB, Krainer, AR, Maus, MV, Marks, P, Mummery, CL, Pettigrew, RI, Rutter, JL, Teichmann, SA, Terzic, A, Urnov, FD, Williams, DA, Wolchok, JD, Lawler, M, Turtle, CJ, Bauer, G & Ioannidis, JPA 2021, , Molecular Therapy - Methods and Clinical Development, vol. 22, pp. 11-14.